- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04741165
Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)
February 2, 2021 updated by: Taizhou Hanzhong biomedical co. LTD
An Open-label, Multicenter, Phase II Clinical Study of HX008 in Combination With Bevacizumab or Lenvatinib in Patients With Advanced Hepatocellular Carcinoma (HCC)
This is a multi-center,open-label study to evaluate the efficacy and safety of anti-PD-1 antibody HX008 plus bevacizumab or lenvatinib in the first-line treatment of patients with unresectable hepatocellular carcinoma.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
72
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jianqiang Cai
- Phone Number: 010-67781331
- Email: caijianqiang188@sina.com
Study Locations
-
-
Anhui
-
Hefei, Anhui, China, 230001
- Not yet recruiting
- The Fist Affiliated Hospital of USTC(Anhui Provincial hospital)
-
-
Beijing
-
Beijing, Beijing, China, 100021
- Recruiting
- Cancer Hospital, Chinese Academy of Medical Sciences
-
Contact:
- Jianqiang Cai
-
Beijing, Beijing, China, 100089
- Recruiting
- Beijing Yuhe Integrated Traditional Chinese and Western Medicine Rehabilitation Hospital
-
Contact:
- Lianhai Zhang
-
-
Guangdong
-
Shenzhen, Guangdong, China, 518116
- Not yet recruiting
- Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center
-
Contact:
- Che Xu
-
-
Heilongjiang
-
Harbin, Heilongjiang, China, 150081
- Recruiting
- Harbin Medical University Cancer Hospital
-
-
Henan
-
Zhengzhou, Henan, China, 450004
- Not yet recruiting
- Henan Cancer Hospital
-
-
Hunan
-
Changsha, Hunan, China, 410000
- Recruiting
- Hunan Provincial People's Hospital
-
Contact:
- Xiaohai Mao
-
Hengyang, Hunan, China, 421000
- Recruiting
- The First Affiliated University of Nanhua University
-
Contact:
- Wenxiang Dai
-
-
Liaoning
-
Shenyang, Liaoning, China, 110000
- Recruiting
- The Sixth People's Hospital of Shenyang
-
-
Shandong
-
Qingdao, Shandong, China, 266000
- Not yet recruiting
- The Affiliated Hospital of Qingdao University
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- Not yet recruiting
- West China Hospital, Sichuan University
-
-
Tianjin
-
Tianjin, Tianjin, China, 300000
- Recruiting
- Tianjin Cancer Hospital
-
Contact:
- Tianqiang Song
-
-
Zhejiang
-
Lishui, Zhejiang, China, 323000
- Recruiting
- The Central Hospital of Lishui City
-
Contact:
- Jianfei Tu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Understood and signed an informed consent form.
- Age ≥ 18 and ≤ 75 years old, male or female.
- Has histologically- or cytologically-confirmed diagnosis of unresectable hepatocellular carcinoma.
- Has Barcelona Clinic Liver Cancer (BCLC) Stage C disease, or BCLC Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy, and not amenable to a curative treatment approach.
- Child-Pugh class A and B (≤7 points).
- Has not received any systematic treatment for HCC.
- Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Score.
- Life expectancy ≥ 3 months.
- Has at least one measurable disease based on RECIST 1.1.
- Has adequate organ function as defined in the protocol.
- Female participants of childbearing potential should have a negative pregnancy within 7 days before the randomization. Male and female participants should agree to use an adequate method of contraception during the experiment and 1 year after the last administration of the test drugs.
Exclusion Criteria:
- Histologically or cytologically documented fibrolamellar hepatocellular carcinoma, sarcoma-like hepatocellular carcinoma, cholangiocarcinoma, etc.
- Diagnosed additional malignancy within 3 years prior to the first dose of trial, with the exception of curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin,curatively resected in situ cervical or non-muscle invasive bladder cancers.
- Has received locoregional therapy or surgery within 4 weeks prior to the first dose of trial treatment; received palliative radiotherapy or herbal medicine within 2 weeks prior to the first dose of trial treatment;
- Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
- HBV-DNA>2000 IU/mL or 10^4 copy/mL; HCV-RNA>10^3 copy/mL.
- Has had esophageal or gastric variceal bleeding within the last 6 months.
- Portal vein tumor thrombus (PVTT) involves both the main trunk and contralateral branch or upper mesenteric vein. Inferior vena cava tumor thrombus.
- Other obvious hemorrhagic tendency or evidence on important coagulation disorder.
- Serious cardiovascular and cerebrovascular diseases.
- Inability to swallow tablets, malabsorption syndrome or any other condition that affects gastrointestinal absorption.
- Serious, uncured wound, active ulcer or untreated bone fracture.
- Uncontrolled pericardial effusion, uncontrolled pleural effusion or clinically obvious moderate peritoneal effusion at screening.
- Has active autoimmune disease that has required systemic treatment in past 2 years.
- Has received a major surgery within 4 weeks prior to the first dose of tiral treatment.
- Has received system treatment with corticosteroids (dose >10mg/day prednison or other therapeutic hormones) within 2 weeks prior to the first dose of trial treatment.
- Has a history of non-infectious pneumonitis that required steroids or has current pneumonitis.
- Has known active tuberculosis (Bacillus tuberculosis)
- Has a history of testing positive for human immunodeficiency virus (HIV), or known acquired immunodeficiency syndrome (AIDS), or stem cell transplantation or organ transplantation.
- Co-infection of HBV and HCV.
- Any serious acute and chronic infection within 4 weeks prior to the first dose of trial treatment, or infection requiring systemic antibacterial, antifungal or antiviral therapy within 2 weeks prior to the first dose of trial treatment.
- Has participated in other anticancer drug clinical trials within 4 weeks.
- Has received a live vaccine within 30 days prior to the first dose of trial treatment.
- According to the judgement of the investigators, there are other factors that may lead to the termination of the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Experimental: HX008+Bevacizumab
Participants receive HX008 200 mg intravenous (IV) every 3 weeks (Q3W) plus bevacizumab 15 mg/kg, IV, Q3W.
|
200 mg administered as IV infusion on Day 1 of each 21-day cycle.
15 mg/kg administered as IV infusion on Day 1 of each 21-day cycle.
Other Names:
|
EXPERIMENTAL: Experimental: HX008+Lenvatinib
Participants receive HX008 200 mg intravenous (IV) every 3 weeks (Q3W) plus lenvatinib 12 mg (for participants with screening body weight ≥60 kg) or 8 mg (for participants with screening body weight <60 kg) orally once a day (QD).
|
200 mg administered as IV infusion on Day 1 of each 21-day cycle.
Administered orally once a day during each 21-day cycle
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR)
Time Frame: Up to approximately 15 months
|
ORR was defined as the percentage of participants who have a complete response (CR) or a partial response (PR), per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by investigators.
|
Up to approximately 15 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease Control Rate (DCR)
Time Frame: up to approximately 15 months
|
DCR was defined as the percentage of participants who have a CR or a PR or a stable disease (SD), per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by investigators.
|
up to approximately 15 months
|
Duration of Response (DOR)
Time Frame: up to approximately 15 months
|
DOR was defined as the time from the first documented evidence of a response of CR or PR, per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by investigators.
|
up to approximately 15 months
|
Progression-free Survival (PFS)
Time Frame: up to approximately 15 months
|
PFS was defined as the time from randomization to the first documented disease progression per RECIST 1.1 assessed by investigators or death due to any cause, whichever occurs first.
|
up to approximately 15 months
|
Overall Survival (OS)
Time Frame: up to approximately 20 months
|
OS was defined as the time from the date of beginning of HX008 administration until date of death from any cause.
|
up to approximately 20 months
|
Time to Disease Progression (TTP)
Time Frame: up to approximately 15 months
|
TTP is defined as the time from randomization to the first documented disease progression per RECIST 1.1 as assessed by investigators.
|
up to approximately 15 months
|
Number of participants with adverse events (AEs)
Time Frame: up to approximately 20 months
|
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment
|
up to approximately 20 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
January 7, 2021
Primary Completion (ANTICIPATED)
April 30, 2022
Study Completion (ANTICIPATED)
October 30, 2022
Study Registration Dates
First Submitted
February 2, 2021
First Submitted That Met QC Criteria
February 2, 2021
First Posted (ACTUAL)
February 5, 2021
Study Record Updates
Last Update Posted (ACTUAL)
February 5, 2021
Last Update Submitted That Met QC Criteria
February 2, 2021
Last Verified
February 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Digestive System Neoplasms
- Liver Diseases
- Liver Neoplasms
- Carcinoma
- Carcinoma, Hepatocellular
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Protein Kinase Inhibitors
- Bevacizumab
- Lenvatinib
Other Study ID Numbers
- HX008-II-HCC-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatocellular Carcinoma
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
Roswell Park Cancer InstituteMerck Sharp & Dohme LLCActive, not recruitingAdvanced Adult Hepatocellular Carcinoma | Child-Pugh Class A | Stage III Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular...United States
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkCompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular Carcinoma | Stage III... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | BCLC Stage C Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI); Genentech, Inc.RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC v7 and other conditionsUnited States, Canada, Puerto Rico
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingAdvanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Metastatic Hepatocellular Carcinoma | BCLC Stage A Hepatocellular CarcinomaUnited States
-
Northwestern UniversityBristol-Myers Squibb; National Cancer Institute (NCI)CompletedStage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular CarcinomaUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science University; American Society of Clinical Oncology; Radiological... and other collaboratorsWithdrawnHepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma AJCC v8 | Stage IB Hepatocellular Carcinoma AJCC v8 | Stage II Hepatocellular Carcinoma AJCC v8 | Stage... and other conditionsUnited States
Clinical Trials on HX008
-
Taizhou Hanzhong biomedical co. LTDNot yet recruiting
-
Taizhou Hanzhong biomedical co. LTDRecruiting
-
Taizhou Hanzhong biomedical co. LTDUnknown
-
Taizhou Hanzhong biomedical co. LTDUnknown
-
Shanghai Miracogen Inc.RecruitingAdvanced Solid TumorsChina
-
Shanghai Miracogen Inc.RecruitingAdvanced Malignant Solid TumorsChina
-
Taizhou HoudeAoke Biomedical Co., Ltd.Unknown
-
Fudan UniversityRecruitingTreatment EfficacyChina
-
Binhui Biopharmaceutical Co., Ltd.Recruiting
-
Taizhou Hanzhong biomedical co. LTDNot yet recruitingMetastatic Colorectal CancerChina